📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-06 15:25
1 analysed today
FollowTelegram
1
Today
151,860
All-time analysed
43,535
Positive
6,743
Negative
92,745
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
6-Year Forensic Audit initiated by SEBI for Nath Bio-Genes (FY21-FY26)
SEBI has appointed CNK & Associates LLP to conduct a forensic audit of Nath Bio-Genes (India) Limited, covering the period from FY 2020-21 to FY 2025-26. The audit will examine books of account and records based on specific matters identified by the regulator. With a market cap of ₹311 Cr and TTM revenue of ₹445 Cr, the company is currently trading at a low P/E of 7.5. The company has stated it is extending full cooperation to the auditors, though the specific triggers for the audit remain undisclosed.
Confidence: HIGH
What changedSEBI has formally initiated a forensic audit of the company's financial records for the past six years.
Why it mattersA forensic audit by the regulator is a high-impact event that indicates concerns regarding financial reporting or governance, which could lead to significant penalties or operational restrictions if irregularities are found.
Audit Period: FY 2020-21 to FY 2025-26Market Cap: ₹311 CrTTM Revenue: ₹445 CrP/E Ratio: 7.5
📅 Short termExpect negative sentiment and potential price volatility in the coming weeks as the market reacts to the regulatory scrutiny.
📈 Long termThe long-term outlook is highly dependent on the audit findings; adverse results could permanently damage the company's valuation and credibility.
⚠ Risk flags
- Regulatory Action
- Governance Risk
- Potential Financial Misstatement
Key Highlights
Forensic audit covers a 6-year period from FY 2020-21 to FY 2025-26
SEBI appointed CNK & Associates LLP as the Forensic Auditor via communication dated August 5, 2026
Company reports TTM revenue of ₹445 Cr and TTM PAT of ₹42 Cr as of the latest period
Audit will examine books of account and records for the specified financial years
👀 What to Watch
Investors should monitor for any subsequent disclosures regarding the findings of the forensic audit or any interim orders from SEBI; avoid reacting to speculation until findings are public.
15% Revenue Growth in Q1 FY27; Maize and Paddy Segments Drive Performance
Nath Bio-Genes reported a strong Q1 FY27 with revenue growing 15% YoY to ₹322.8 Cr, driven by significant gains in Maize and Paddy segments. EBITDA increased 17% to ₹35.1 Cr, maintaining an 11% margin despite a 31% surge in finance costs. The Maize segment was a standout performer with 59% value growth, while Paddy value grew 34% due to premium product contributions. This quarter is highly material, representing approximately 72.5% of the company's TTM revenue, highlighting the business's extreme seasonality.
Confidence: HIGH
What changedThe company released its Q1 FY27 investor presentation, showing strong double-digit growth in revenue and EBITDA led by non-cotton segments.
Why it mattersQ1 is the most critical quarter for seed companies due to the Kharif sowing season; strong performance here is essential for meeting annual growth targets.
Q1 FY27 Revenue: ₹322.8 CrQ1 Revenue vs TTM Revenue: 72.5%Maize Value Growth: 59%EBITDA Growth (YoY): 17%Finance Cost Increase: 31%Net Debt (FY26): ₹51 Cr
📅 Short termThe stock may see positive momentum as the company successfully navigated the peak season with strong volume and value growth in key crops.
📈 Long termThe shift toward high-margin segments like vegetables and premium hybrids is structurally positive for long-term margin expansion.
⚠ Risk flags
- Extreme seasonality (heavy reliance on Q1)
- Rising finance costs
- Monsoon dependency for seed demand
Key Highlights
Q1 FY27 Revenue reached ₹322.8 Cr, up 15% from ₹280.2 Cr in Q1 FY26.
Maize segment recorded 44% volume growth and 59% value growth YoY.
Paddy segment registered 19% volume growth and 34% value growth YoY.
EBITDA grew 17% YoY to ₹35.1 Cr, outpacing revenue growth.
Finance costs increased by 31% YoY to ₹3.8 Cr.
👀 What to Watch
Watch for the company's ability to maintain margins in the off-peak quarters and monitor the impact of rising finance costs on net profitability.
Nath Bio-Genes Q1 FY27: Revenue Up 15.2% YoY to ₹322.84 Cr, PAT at ₹32.66 Cr
Nath Bio-Genes reported a strong start to FY27 with standalone revenue growing 15.2% YoY to ₹322.84 Cr for the June quarter. Net profit increased by 11.8% to ₹32.66 Cr, resulting in an EPS of ₹17.18 compared to ₹15.37 in the previous year. This quarter is seasonally the most significant for the company, contributing approximately 72.5% of its TTM revenue. Despite a rise in finance costs to ₹3.79 Cr, the company maintained steady operational margins.
Confidence: HIGH
What changedThe company has delivered double-digit growth in its most critical quarter (Q1), which typically accounts for the bulk of its annual earnings.
Why it mattersFor a seed company, Q1 performance is the primary indicator of fiscal health; strong revenue realization here mitigates risks for the quieter remaining quarters.
Revenue (Q1 FY27): ₹322.84 CrNet Profit (Q1 FY27): ₹32.66 CrYoY Revenue Growth: 15.2%Q1 Revenue vs TTM Revenue: 72.5%EPS (Q1 FY27): ₹17.18
📅 Short termThe stock may see positive sentiment as the results confirm growth in the peak sowing season.
📈 Long termLong-term value depends on the company's ability to diversify revenue beyond the monsoon-dependent Q1 and scale its international joint venture in Uzbekistan.
⚠ Risk flags
- High seasonal concentration of revenue
- Rising finance costs
- Susceptibility to monsoon patterns
Key Highlights
Revenue from operations grew to ₹322.84 Cr from ₹280.17 Cr in the same quarter last year.
Net profit for the quarter stood at ₹32.66 Cr, up from ₹29.21 Cr YoY.
Selling and Distribution expenses increased to ₹107.97 Cr, reflecting peak seasonal marketing activity.
Finance costs rose by 31% YoY to ₹3.79 Cr from ₹2.89 Cr.
The 33rd Annual General Meeting (AGM) is scheduled for September 24, 2026.
👀 What to Watch
Watch for the management's commentary on monsoon impact and the progress of high-margin segments like vegetables and hybrid paddy, which are central to their 15% annual growth target.
Nath Bio-Genes FY26 Revenue Grows 19% to ₹4,316 Mn; Margins Contract to 12%
Nath Bio-Genes reported a strong 19% YoY revenue growth for FY26, reaching ₹4,316 million, driven by robust performance in Cotton (+28% value) and Maize (+78% value). However, profitability was under pressure as EBITDA remained flat at ₹525 million and Gross Margins compressed from 63% to 56%. A key highlight is the international expansion milestone, with Uzbekistan contributing ₹150 million to the top line for the first time. Despite the revenue jump, PAT (adjusted) declined by 8% YoY to ₹384 million.
Key Highlights
Revenue increased by 19% YoY to ₹4,316 Mn, while EBITDA remained stagnant at ₹525 Mn.
Cotton Bt volumes grew 22.35% with average realization rising to ₹293/kg.
Gross Margin saw a significant contraction to 56% in FY26 from 63% in the previous year.
International operations in Uzbekistan achieved a landmark ₹150 Mn revenue contribution.
Net Debt increased significantly to ₹510 Mn from ₹235 Mn in FY25.
👀 What to Watch
Investors should monitor the company's ability to recover margins and manage rising debt levels despite healthy top-line growth. The successful scale-up in Uzbekistan and growth in the Maize segment are positive long-term indicators to watch.
Nath Bio-Genes FY26 Revenue Up 19% to ₹431.6 Cr; Recommends ₹2 Dividend
Nath Bio-Genes (India) Limited reported a 19.1% growth in annual revenue for FY26, reaching ₹431.60 crore compared to ₹362.31 crore in FY25. Annual net profit saw a modest increase of 5.4% to ₹44.43 crore, despite a weaker fourth quarter where profit dipped to ₹3.79 crore. The Board has recommended a dividend of ₹2 per share (20% of face value). A significant management update includes the more than doubling of the Managing Director's remuneration to ₹1.44 crore per annum.
Key Highlights
Annual Revenue from operations grew 19.1% YoY to ₹431.60 crore from ₹362.31 crore.
Full-year Net Profit increased to ₹44.43 crore compared to ₹42.14 crore in the previous fiscal.
Recommended a final dividend of ₹2.00 per equity share (20%) for FY 2025-26.
Managing Director's annual remuneration increased by 118% from ₹66 lakhs to ₹1.44 crore.
Inventory levels rose significantly to ₹444.60 crore from ₹330.71 crore YoY, indicating aggressive positioning for the next season.
👀 What to Watch
Investors should view the steady annual top-line growth and dividend payout positively, though the sharp hike in executive pay and rising inventory levels warrant close monitoring. The stock remains a play on the Indian agricultural cycle and seed demand.
Nath Bio-Genes Q3 Revenue Surges 79% to ₹660 Mn; PAT Up 67% YoY
Nath Bio-Genes reported a robust 79% YoY revenue growth in Q3FY26, reaching ₹660 million, primarily driven by a massive 142% value growth in the Maize segment. While Q3 PAT rose 67% to ₹45 million, EBITDA margins faced pressure, declining to 13% from 20% YoY. For 9MFY26, the company achieved a 23% revenue increase to ₹3,859 million, though PAT growth remained muted at 1%. The company is successfully diversifying its portfolio, with significant volume gains in Cotton (21%), Paddy (8%), and Vegetables (43%).
Key Highlights
Q3FY26 Revenue increased by 79% YoY to ₹660 million; 9MFY26 Revenue up 23% to ₹3,859 million.
Maize segment witnessed exceptional growth with volume up 94.77% and value up 141.98% YoY.
Q3 EBITDA margin compressed to 13% from 20% YoY, while 9M EBITDA margin stood at 14%.
Cotton segment remains the primary driver with 25.26% value growth in the first nine months.
Vegetable seeds emerged as a fast-growing segment with a 52.08% increase in value during 9MFY26.
👀 What to Watch
Investors should cheer the strong top-line growth and diversification into high-value crops like Maize and Vegetables, but should closely monitor the impact of rising costs on EBITDA margins.
Nath Bio-Genes Q3 Standalone PAT Jumps 172% to ₹7.23 Cr; Consolidated Profit Declines
Nath Bio-Genes (India) Limited reported a robust standalone performance for Q3 FY26, with revenue growing 79% YoY to ₹65.96 crore and PAT surging 172% to ₹7.23 crore. However, the consolidated net profit for the quarter fell to ₹1.60 crore from ₹2.65 crore YoY, indicating significant losses or expenses within subsidiaries. For the nine-month period ended December 2025, consolidated revenue stood at ₹383.51 crore, up from ₹312.94 crore. Investors should note a qualified auditor's opinion regarding unassessed liabilities from new Labour Codes and the absence of actuarial valuations for employee benefits.
Key Highlights
Standalone Revenue for Q3 FY26 increased 78.9% YoY to ₹65.96 crore from ₹36.87 crore.
Standalone Net Profit for the quarter surged to ₹7.23 crore compared to ₹2.66 crore in the same period last year.
Consolidated Net Profit for Q3 FY26 dropped to ₹1.60 crore, down from ₹2.65 crore in Q3 FY25.
9M FY26 Consolidated Revenue grew 22.5% YoY to ₹383.51 crore from ₹312.94 crore.
Auditors issued a qualified opinion due to the lack of financial impact assessment for new Labour Codes effective Nov 2025.
👀 What to Watch
Investors should investigate the widening gap between standalone and consolidated profits, as subsidiaries appear to be significantly impacting the bottom line. While standalone growth is strong, the auditor's qualification on labor code liabilities and missing actuarial valuations warrants caution regarding future provisions.
